NO308742B1 - Morfolintachykininreseptorantagonister og farmasøytisk preparat inneholdende disse - Google Patents

Morfolintachykininreseptorantagonister og farmasøytisk preparat inneholdende disse

Info

Publication number
NO308742B1
NO308742B1 NO962523A NO962523A NO308742B1 NO 308742 B1 NO308742 B1 NO 308742B1 NO 962523 A NO962523 A NO 962523A NO 962523 A NO962523 A NO 962523A NO 308742 B1 NO308742 B1 NO 308742B1
Authority
NO
Norway
Prior art keywords
substituted
receptor antagonists
tachykinin receptor
group
pharmaceutical preparations
Prior art date
Application number
NO962523A
Other languages
English (en)
Norwegian (no)
Other versions
NO962523L (no
NO962523D0 (no
Inventor
Conrad P Dorn
Paul E Finke
Jeffrey J Hale
Malcolm Maccoss
Sander G Mills
Shrenik K Shah
Mark Stuart Chambers
Timothy Harrison
Tamara Ladduwahetty
Brian John Williams
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22617632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO308742(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO962523D0 publication Critical patent/NO962523D0/no
Publication of NO962523L publication Critical patent/NO962523L/no
Publication of NO308742B1 publication Critical patent/NO308742B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO962523A 1993-12-17 1996-06-14 Morfolintachykininreseptorantagonister og farmasøytisk preparat inneholdende disse NO308742B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16988993A 1993-12-17 1993-12-17
PCT/US1994/014497 WO1995016679A1 (en) 1993-12-17 1994-12-13 Morpholine and thiomorpholine tachykinin receptor antagonists

Publications (3)

Publication Number Publication Date
NO962523D0 NO962523D0 (no) 1996-06-14
NO962523L NO962523L (no) 1996-08-16
NO308742B1 true NO308742B1 (no) 2000-10-23

Family

ID=22617632

Family Applications (3)

Application Number Title Priority Date Filing Date
NO962523A NO308742B1 (no) 1993-12-17 1996-06-14 Morfolintachykininreseptorantagonister og farmasøytisk preparat inneholdende disse
NO2004003C NO2004003I2 (no) 1993-12-17 2004-04-21 Aprepitant, eventuelt i form av et farmasøytisk akseptabelt salt
NO2018011C NO2018011I2 (no) 1993-12-17 2018-04-04 Aprepitant, eventuelt i form av et farmasøytisk akseptabelt salt - forlenget SPC

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2004003C NO2004003I2 (no) 1993-12-17 2004-04-21 Aprepitant, eventuelt i form av et farmasøytisk akseptabelt salt
NO2018011C NO2018011I2 (no) 1993-12-17 2018-04-04 Aprepitant, eventuelt i form av et farmasøytisk akseptabelt salt - forlenget SPC

Country Status (40)

Country Link
EP (1) EP0734381B1 (cs)
JP (1) JP3245424B2 (cs)
KR (1) KR100335704B1 (cs)
CN (1) CN1057296C (cs)
AT (1) ATE194336T1 (cs)
AU (1) AU701862B2 (cs)
BG (1) BG64775B1 (cs)
BR (1) BR9408351A (cs)
CA (1) CA2178949C (cs)
CO (1) CO4340628A1 (cs)
CY (2) CY2203B1 (cs)
CZ (1) CZ295381B6 (cs)
DE (2) DE122004000019I1 (cs)
DK (1) DK0734381T3 (cs)
ES (1) ES2147840T3 (cs)
FI (1) FI109532B (cs)
FR (1) FR04C0010I2 (cs)
GR (1) GR3034095T3 (cs)
HR (1) HRP941000B9 (cs)
HU (1) HU224014B1 (cs)
IL (1) IL111960A (cs)
LT (1) LTC0734381I2 (cs)
LU (1) LU91069I9 (cs)
LV (1) LV11617B (cs)
MY (1) MY115164A (cs)
NL (1) NL300146I2 (cs)
NO (3) NO308742B1 (cs)
NZ (1) NZ278222A (cs)
PL (1) PL182521B1 (cs)
PT (1) PT734381E (cs)
RO (1) RO118203B1 (cs)
RU (1) RU2201924C2 (cs)
SA (1) SA95150523B1 (cs)
SI (1) SI0734381T1 (cs)
SK (1) SK282800B6 (cs)
TW (1) TW419471B (cs)
UA (1) UA47397C2 (cs)
WO (1) WO1995016679A1 (cs)
YU (1) YU49037B (cs)
ZA (1) ZA9410008B (cs)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3071467B2 (ja) * 1993-12-29 2000-07-31 メルク シヤープ エンド ドーム リミテツド 置換モルホリン誘導体およびその治療剤としての使用
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
WO1995030674A1 (en) * 1994-05-05 1995-11-16 Merck Sharp & Dohme Limited Morpholine derivatives and their use as antagonists of tachikinins
JP2002502351A (ja) * 1994-08-15 2002-01-22 メルク シヤープ エンド ドーム リミテツド モルホリン誘導体及び治療薬としてそれらの使用
GB9417956D0 (en) * 1994-09-02 1994-10-26 Merck Sharp & Dohme Therapeutic agents
GB9505491D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9511031D0 (en) * 1995-06-01 1995-07-26 Merck Sharp & Dohme Chemical process
GB9513118D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9523244D0 (en) * 1995-11-14 1996-01-17 Merck Sharp & Dohme Therapeutic agents
US5750549A (en) * 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
ZA985765B (en) 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
DE69838421D1 (en) * 1997-07-02 2007-10-25 Merck & Co Inc Polymorphe form des tachykininrezeptorantagonisten 2-(r)-(1-(r)-(3,5-bis(trifluormethyl)phenyl)ethoxy)-3-(s)-(4-fluor)phenyl-4-(3-5-oxo-1h,4h-1,2,4-triazolo)methylmorpholin
GB9813025D0 (en) * 1998-06-16 1998-08-12 Merck Sharp & Dohme Chemical synthesis
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
WO2000050401A1 (en) 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
HRP20010603A2 (en) * 1999-02-24 2002-08-31 Hoffmann La Roche Phenyl-and pyridinyl derivatives
US6291465B1 (en) 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
ES2304984T3 (es) 1999-11-03 2008-11-01 Amr Technology, Inc. Tetra-hidroisoquinolinas de sustitucion arilica y heteroarilica y su utilizacion para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6452001B2 (en) 2000-05-25 2002-09-17 Hoffmann-La Roche Inc. Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
AR030284A1 (es) 2000-06-08 2003-08-20 Merck & Co Inc Proceso para la sintesis de (2r, 2-alfa-r,3a) -2-[1-(3,5-bis(trifluorometil) fenil) etoxi]-3-(4-fluorofenil)-1,4-oxazina; dicho compuesto y sus formas polimorficas
US7084152B2 (en) 2000-07-11 2006-08-01 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
DE60134749D1 (de) 2000-07-14 2008-08-21 Hoffmann La Roche N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
YU39503A (sh) 2000-11-22 2006-05-25 F. Hoffmann-La Roche Ag. Derivati pirimidina
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
ATE401333T1 (de) 2001-05-14 2008-08-15 Hoffmann La Roche 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
CN100358878C (zh) * 2001-12-07 2008-01-02 辉瑞产品公司 治疗化合物的柠檬酸盐及其药物组合物
UA76810C2 (uk) * 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
AR039625A1 (es) * 2002-04-18 2005-03-02 Merck & Co Inc Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona
AU2004208483B8 (en) * 2003-01-31 2008-04-03 F. Hoffmann-La Roche Ag Crystalline modifications of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lamda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
GB0310881D0 (en) * 2003-05-12 2003-06-18 Merck Sharp & Dohme Pharmaceutical formulation
WO2005002577A1 (en) 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
ES2246687B2 (es) 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
MX2007000428A (es) 2004-07-15 2008-03-05 Amr Technology Inc Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina.
JP4767973B2 (ja) 2005-02-22 2011-09-07 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ１アンタゴニスト
ES2320590T3 (es) 2005-03-23 2009-05-25 F. Hoffmann-La Roche Ag Metabolitos para antagonistas nk-1 para emesis.
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
WO2007011820A2 (en) 2005-07-15 2007-01-25 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007039420A1 (en) 2005-09-23 2007-04-12 F. Hoffmann-La Roche Ag Novel dosage formulation
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007044829A2 (en) 2005-10-06 2007-04-19 Dr. Reddy's Laboratories Ltd. Preparation of aprepitant
US9227958B2 (en) * 2006-02-03 2016-01-05 Glenmark Pharmaceuticals Limited Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2057151A4 (en) * 2006-08-28 2010-07-21 Hetero Drugs Ltd PROCESS FOR PURIFYING APREPITANT
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
SI2805945T1 (sl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
WO2008128891A1 (en) 2007-04-20 2008-10-30 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
CA2695211A1 (en) 2007-08-07 2009-02-12 F. Hoffmann-La Roche Ag Pyrrolidine aryl-ether as nk3 receptor antagonists
CA2716080C (en) 2008-02-20 2016-12-13 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
CA2717509A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
CL2009002208A1 (es) 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
EP3222628A1 (en) 2008-12-23 2017-09-27 Gilead Pharmasset LLC Nucleoside phosphoramidates
MX2011006892A (es) 2008-12-23 2011-07-20 Pharmasset Inc Sintesis de nucleosidos de purina.
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
MX2011011907A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2, 3,4-tetrahidroisoquinolina y uso de la misma.
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
EA023838B1 (ru) 2009-10-14 2016-07-29 Мерк Шарп Энд Домэ Корп. ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
ES2551944T3 (es) 2010-03-31 2015-11-24 Gilead Pharmasset Llc (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2H)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato de isopropilo cristalino
US8487102B2 (en) 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
ES2376564B1 (es) 2010-08-12 2013-01-24 Manuel Vicente Salinas Martín Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
ES2616752T3 (es) 2010-09-23 2017-06-14 Nuformix Limited Composición y cocristal de aprepitant L-prolina
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2012146692A1 (en) 2011-04-29 2012-11-01 Sandoz Ag Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN104159584A (zh) 2011-11-25 2014-11-19 诺弗米克斯有限公司 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
EP2837381A4 (en) 2011-12-13 2015-12-09 Servicio Andaluz De Salud USE OF MEDICAMENTS FOR THE TREATMENT OF CANCER THAT CHANGE THE PERITUMORAL ENVIRONMENT
CZ304770B6 (cs) 2012-03-13 2014-10-08 Zentiva, K.S. Způsob výroby 3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluormethyl)fenyl)ethoxy)-3-(4-fluorfenyl)morfolino)methyl)-1H-1,2,4-triazol-5(4H)-onu (Aprepitantu) v polymorfní formě II
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
PT2925888T (pt) 2012-11-28 2017-12-13 Merck Sharp & Dohme Composições e métodos para tratamento do cancro
EP2935263B1 (en) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
ES2493693B1 (es) 2013-02-11 2015-07-07 Servicio Andaluz De Salud Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CN103694146B (zh) * 2013-12-04 2015-10-28 深圳万乐药业有限公司 2-(2-氯-1-亚乙基)酰肼甲酸甲酯的制备方法
ES2541870B1 (es) 2013-12-27 2016-05-12 Servicio Andaluz De Salud Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
US10005803B2 (en) 2015-10-06 2018-06-26 Helsinn Healthcare Sa Crystalline forms of fosnetupitant
PE20190347A1 (es) 2016-06-06 2019-03-07 Helsinn Healthcare Sa Formulaciones inyectables fisiologicamente balanceadas de fosnetupitant
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
KR20220165251A (ko) 2020-04-03 2022-12-14 네르 쎄라퓨틱스 리미티드 패혈증, 패혈성 쇼크, 급성 호흡 곤란 증후군 (ards) 또는 다발성 기관 기능장애 증후군 (mods)으로부터 선택된 질환을 치료하기 위한 nk-1 수용체 길항제
US11872222B2 (en) 2020-06-02 2024-01-16 Nerre Therapeutics Limited Uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534915B1 (fr) * 1982-10-26 1985-10-25 Lafon Labor Nouveaux derives de 2-(phenoxymethyl)-morpholine, utilisation en therapeutique et procede de preparation
US5459270A (en) * 1991-08-20 1995-10-17 Merck Sharp & Dohme Limited Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
EP0683767B1 (en) * 1993-02-18 1998-06-03 MERCK SHARP & DOHME LTD. Azacyclic compounds, compositions containing them and their use as tachykinin antagonists

Also Published As

Publication number Publication date
IL111960A (en) 1999-12-22
DE122004000019I1 (de) 2004-09-30
LTC0734381I2 (lt) 2017-04-25
LV11617B (en) 1997-04-20
KR960706483A (ko) 1996-12-09
IL111960A0 (en) 1995-03-15
HRP941000B9 (hr) 2014-11-07
NL300146I1 (nl) 2004-06-01
FR04C0010I2 (fr) 2004-12-17
NO2018011I2 (no) 2018-12-14
WO1995016679A1 (en) 1995-06-22
HUT76476A (en) 1997-09-29
BG64775B1 (bg) 2006-03-31
LV11617A (lv) 1996-12-20
TW419471B (en) 2001-01-21
ES2147840T3 (es) 2000-10-01
SA95150523B1 (ar) 2006-03-15
CA2178949A1 (en) 1995-06-22
NO2018011I1 (no) 2018-04-04
GR3034095T3 (en) 2000-11-30
BR9408351A (pt) 1997-08-26
HU224014B1 (hu) 2005-04-28
PL315153A1 (en) 1996-10-14
DE69425161T2 (de) 2001-02-15
HRP941000B1 (en) 2001-04-30
CN1057296C (zh) 2000-10-11
NL300146I2 (nl) 2004-07-01
FI962489A7 (fi) 1996-08-13
DK0734381T3 (da) 2000-09-18
RU2201924C2 (ru) 2003-04-10
CO4340628A1 (es) 1996-07-30
AU1437595A (en) 1995-07-03
CN1142819A (zh) 1997-02-12
YU74694A (sh) 1997-08-22
MY115164A (en) 2003-04-30
SK282800B6 (sk) 2002-12-03
YU49037B (sh) 2003-07-07
CY2203B1 (en) 2002-11-08
CY2004012I1 (el) 2010-07-28
EP0734381B1 (en) 2000-07-05
ZA9410008B (en) 1996-07-15
FI962489A0 (fi) 1996-06-14
HU9601634D0 (en) 1996-08-28
CY2004012I2 (el) 2017-04-05
NO962523L (no) 1996-08-16
LU91069I9 (en) 2018-07-24
BG100715A (bg) 1997-01-31
NO2004003I2 (no) 2006-10-04
PT734381E (pt) 2000-12-29
KR100335704B1 (ko) 2002-11-18
HRP941000A2 (en) 1997-06-30
HK1009046A1 (en) 1999-05-21
NO2004003I1 (no) 2004-06-28
SI0734381T1 (en) 2000-10-31
LU91069I2 (fr) 2004-04-07
EP0734381A1 (en) 1996-10-02
RO118203B1 (ro) 2003-03-28
CA2178949C (en) 2006-03-21
SK75396A3 (en) 1996-12-04
JP3245424B2 (ja) 2002-01-15
ATE194336T1 (de) 2000-07-15
NZ278222A (en) 1998-05-27
FI109532B (fi) 2002-08-30
NO962523D0 (no) 1996-06-14
AU701862B2 (en) 1999-02-04
PL182521B1 (pl) 2002-01-31
DE69425161D1 (de) 2000-08-10
CZ295381B6 (cs) 2005-07-13
FR04C0010I1 (cs) 2004-05-21
UA47397C2 (uk) 2002-07-15
LTPA2004002I1 (lt) 2016-11-10
JPH09506628A (ja) 1997-06-30
CZ177296A3 (en) 1996-12-11

Similar Documents

Publication Publication Date Title
NO308742B1 (no) Morfolintachykininreseptorantagonister og farmasøytisk preparat inneholdende disse
NO305698B1 (no) Morfolin-tachykinin-reseptorantagonister
NO308248B1 (no) Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat
NO911525D0 (no) Nye 2,9-disubstituerte-4h-pyrido(1,2-a)pyrimidin-4-oner.
NO973652D0 (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyre og derivater som tachykininreseptor-antagonist
WO1999062893A3 (de) Neue neurokininantagonisten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE69402703D1 (de) 3-(INDOL-3-YL) PROPENSäURDERIVATE, DIE ALS NMDA- ANTAGONISTEN NÜTZLICH SIND
ATE364594T1 (de) (4-acylaminopiperidin-1-yl)acetamide als neurokininantagonisten

Legal Events

Date Code Title Description
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: APREPITANT, EVENTUELT I FORM AV ET FARMASOYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU103262001 NO-006 20031215; FIRST REG. NO/DATE: NO , EU103262001-006 20031113

Spc suppl protection certif: 2004003

Filing date: 20040421

Extension date: 20181113

Effective date: 20061003

MK1K Patent expired
SPCK Change in the validity period of an spc

Free format text: PRODUCT NAME: APREPITANT, EVENTUELT I FORM AV ET FARMASOYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU103262001 NO-006 20031215; FIRST REG. NO/DATE: NO , EU103262001-006 20031113

Spc suppl protection certif: 2004003

Filing date: 20040421

SPCE Application to extend a supplementary protection certificate (spc)

Free format text: PRODUCT NAME: APREPITANT, EVENTUELT I FORM AV ET FARMASOYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU/1/03/262/001-006 20031215; FIRST REG. NO/DATE: EU , EU/1/03/262/001-006 20031113

Spc suppl protection certif: 2018011

Filing date: 20180404

Extension date: 20190513

SPCX Expiry of an spc

Spc suppl protection certif: 2004003

Effective date: 20181113

SPCH Extension of a supplementary protection certificate (spc) granted

Free format text: PRODUCT NAME: APREPITANT, EVENTUELT I FORM AV ET FARMASOYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU/1/03/262/001-006 20031215; FIRST REG. NO/DATE: EU , EU/1/03/262/001-006 20031113

Spc suppl protection certif: 2018011

Filing date: 20180404

Extension date: 20190513

SPCZ Expiry of an extension of a supplementary protection certificate (spc)

Spc suppl protection certif: 2018011

Effective date: 20190513